A data-driven approach to complement the A/T/(N) classification system using CSF biomarkers

CNS Neurosci Ther. 2024 Feb;30(2):e14382. doi: 10.1111/cns.14382. Epub 2023 Jul 27.

Abstract

Aims: The AT(N) classification system not only improved the biological characterization of Alzheimer's disease (AD) but also raised challenges for its clinical application. Unbiased, data-driven techniques such as clustering may help optimize it, rendering informative categories on biomarkers' values.

Methods: We compared the diagnostic and prognostic abilities of CSF biomarkers clustering results against their AT(N) classification. We studied clinical (patients from our center) and research (Alzheimer's Disease Neuroimaging Initiative) cohorts. The studied CSF biomarkers included Aβ(1-42), Aβ(1-42)/Aβ(1-40) ratio, tTau, and pTau.

Results: The optimal solution yielded three clusters in both cohorts, significantly different in diagnosis, AT(N) classification, values distribution, and survival. We defined these three CSF groups as (i) non-defined or unrelated to AD, (ii) early stages and/or more delayed risk of conversion to dementia, and (iii) more severe cognitive impairment subjects with faster progression to dementia.

Conclusion: We propose this data-driven three-group classification as a meaningful and straightforward approach to evaluating the risk of conversion to dementia, complementary to the AT(N) system classification.

Keywords: Alzheimer's disease; cerebrospinal fluid; clustering analysis; early detection; machine learning; mild cognitive impairment.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Alzheimer Disease* / diagnostic imaging
  • Amyloid beta-Peptides
  • Biomarkers
  • Cognitive Dysfunction* / diagnostic imaging
  • Disease Progression
  • Humans
  • Peptide Fragments
  • tau Proteins

Substances

  • Amyloid beta-Peptides
  • tau Proteins
  • Biomarkers
  • Peptide Fragments